Mission Therapeutics Strengthens Board with Appointments of Michael Moore and Fritz Frickel

09-Oct-2012 - United Kingdom

Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer, has announced the appointment of Dr Michael Moore as Executive Chairman and Fritz Frickel as Non-Executive Director.

Dr Moore brings extensive experience to Mission at a formative phase of the company’s development.

Following an earlier academic career principally at the Paterson Institute for Cancer Research (University of Manchester), Dr Moore has more than two decades of senior management experience in the biotechnology sector, as Chief Scientific Officer of Xenova Group plc and more recently as Chief Executive Officer of Piramed, the UK bioscience company acquired by F Hoffmann-La Roche in 2008. Dr Moore also serves as a Non-Executive Director of several companies including PsiOxus Therapeutics. He is also a member of the Cancer Research UK Science Committee.

Dr Fritz Frickel joins the Mission Board as a non-executive director. Currently an independent advisor to venture capital firms, biotech start-ups and universities, Dr Frickel was formerly Senior Vice-President of R&D and acting CEO of Alantos which was acquired by Amgen. Other senior pharma roles have included SVP of research at Abbott, world-wide head of research at BASF and head of clinical, pharmaceutical and regulatory development at Knoll. Dr Frickel served as non-executive director of RespiVert, an Imperial College spin-out, until its acquisition by Janssen Biotech Inc. in 2010 and is currently a director of new start-up company TopiVert.

https://www.bionity.com/en/news/140001/mission-therapeutics-strengthens-board-with-appointments-of-michael-moore-and-fritz-frickel.html